Jean Yang

• Identified the strengths of key accounts and supported establishment of Training Center of Excellence (TCoE) in CHGH and VGHTP for APAC region.
• Driving messaging alignment among KOLs for new procedure (Mitral Valve in Valve) reimbursement withing 2 years and effective in Nov. 2025.
• Sales team establishment from recruiting to clinical/ sales education (CT measurement and on-site clinical support)

Facilitated market development through therapy awareness campaigns connecting district hospitals with medical centers to accelerate patient access journey.

• Coordinated 6 therapy awareness symposiums attended by over 50 cardiologists to promote knowledge sharing.
• Established 2 pathways to accelerate patient access to TAVI therapy.

Portfolio management and clinical marketing for multiple generation of SAPIEN series in JAPAC region.

• Conducted product messaging campaign for sales teams in Korea, Thailand, India, China, and Taiwan, enhancing clinical and health economic based knowledge and sales effectiveness.
• Coordinated new product launch in Korea and Australia through Launch Excellence process, ensuring alignment with market needs and global standards.
• Leading product messaging campaign internally with sales team and externally with third party conference eg. PCR London Valves and Tokyo Valves.

Established new hospital accounts and developed KOLs to increase therapy penetration and SAPIEN 3 users throughout Taiwan.

• 2021 JAPAC President Club Award winner with 107% achievement and 39% growth rate.
• KOLs endorsement in AmCham Patient day and TSCI.
• Converted three existing accounts (NTUH, CGMHLK, VGHTC) from competitors to SAPIEN3 with 70+% market share.
• Penetrated CMUH and CGMHKS and assisted new heart teams establishment in TMUH and SHH.

• Portfolio management with strategic positioning in reimbursement categories: full coverage/ balanced billing/ self-payment, impacting 24M revenue.
• Transitioned business model from distributor sales to direct sales through internal collaboration with SCM, FA, global BU and external coordination with distributor within 6 months.

• Collaborated with KOLs to initiate new procedure code for TAVI in NHI reimbursement system, effective May 2017.
• Developed 8 new TAVI centers (CGMH-LK, SKH, MMH, FEMH, CGH, CMUH, NCKUH, CGMH-KS) with certification.

Reviewed safety and efficacy of cardiovascular and ophthalmic devices, including heart valves and intraocular lenses, ensuring compliance with regulatory standards.

Investigated micro RNA as a biomarker for acute kidney injury to enhance diagnostic accuracy.